Salus

Sailu Medical, established in October 2020, focuses on developing upstream sequencing platforms with independent intellectual property rights and has built a globally leading super-resolution spatial omics platform based on it, enabling the independent development of genomics and spatial omics products as well as their transformation in scientific research and clinical applications. The scientist entrepreneurial team led by Dr. Luoyang Zhao has overcome previous bottlenecks in sequencing products related to throughput, cost, resolution, and automation while achieving the localization of the platform. In just two years since its establishment, the company has rapidly developed and now possesses internationally leading sequencing and omics platforms, providing comprehensive solutions for mid- and downstream applications, and has already initiated collaborations with multiple institutions.